文献速递临床试验与 GCP流行病学与生物统计

将肝脏终点纳入心血管与肾脏疾病临床试验

Integrating liver endpoints in clinical trials of cardiovascular and kidney disease.
PubMed 文献 · Nat Med · 2024-09-03

本文为观点文章,指出代谢功能障碍相关脂肪性肝病(MASLD)常与心血管疾病、代谢紊乱和慢性肾脏病共存,可能共享机制与危险因素。作者呼吁在机制合理且肝脏与心血管安全性有数据支持时,将MASLD患者纳入心-肾-代谢试验并测量肝脏结局,讨论了这一新范式对试验设计与监管审批的影响,并概述实施挑战与未来试验开展建议。

要点

  • MASLD常与心血管疾病、代谢紊乱和慢性肾脏病序贯或同时出现,可能共享机制与危险因素。
  • 作者呼吁在机制合理且肝脏与心血管安全性有数据支持时,将MASLD患者纳入心-肾-代谢试验并测量肝脏结局。
  • 文章讨论了该新范式对临床试验设计与监管审批的影响,并概述实施挑战与未来试验开展建议。

核心结论

  • 作者呼吁在数据提示机制上合理的获益且肝脏与心血管安全性有支持时,将MASLD患者纳入心-肾-代谢临床试验并测量肝脏结局。

研究设计与样本

  • 本文为观点文章(Perspective),讨论将肝脏终点纳入心血管与肾脏疾病临床试验的新范式。

主要发现

  • 代谢功能障碍相关脂肪性肝病(MASLD)常与心血管疾病、代谢紊乱和慢性肾脏病序贯或同时出现,可能共享机制与危险因素。
  • growing evidence提示新疗法可能对上述疾病均有获益,但试验申办方与研究者倾向于不纳入合并症患者,尤其是肝脏疾病患者。

临床怎么用

  • 作者建议在数据提示机制上合理的获益且肝脏与心血管安全性有支持时,将MASLD患者纳入心-肾-代谢试验并测量肝脏结局。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The intersection of cardiovascular disease, metabolic disorders and chronic kidney disease represents a complex clinical picture challenging healthcare systems worldwide. Metabolic-dysfunction-associated steatotic liver disease (MASLD) often manifests sequentially or concomitantly with these diseases, and may share underlying mechanisms and risk factors. Growing evidence suggests that new therapies could have benefits across these diseases, but trial sponsors and investigators tend to be reluctant to include patients with comorbidities-particularly liver diseases-in clinical trials. In this Perspective, we call for inclusion of patients with MASLD and measurement of liver outcomes in cardio-kidney-metabolic trials, when data suggest mechanistically plausible benefits and liver and cardiovascular safety. We discuss the implications of this new paradigm for clinical trial design and considerations for regulatory approval. Finally, we outline the challenges to implementing such an approach and provide recommendations for future clinical trial conduct.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Zannad F, Sanyal AJ, Butler J, et al. Integrating liver endpoints in clinical trials of cardiovascular and kidney disease. Nat Med. 2024. PMID: 39227442. doi:10.1038/s41591-024-03223-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。